---
title: "Pfizer Inc. (NYSE:PFE) Stake Raised by Delta Asset Management LLC TN"
description: "Delta Asset Management LLC TN increased its stake in Pfizer Inc. (NYSE:PFE) by 15.8% in Q4, owning 97,994 shares valued at $2.6 million. Other hedge funds also adjusted their positions. Analyst rating"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/233440518.md"
published_at: "2025-03-27T10:51:49.000Z"
---

# Pfizer Inc. (NYSE:PFE) Stake Raised by Delta Asset Management LLC TN

> Delta Asset Management LLC TN increased its stake in Pfizer Inc. (NYSE:PFE) by 15.8% in Q4, owning 97,994 shares valued at $2.6 million. Other hedge funds also adjusted their positions. Analyst ratings for Pfizer include a mix of buy and hold ratings, with a consensus rating of "Moderate Buy" and an average price target of $31.92. Insider Ronald E. Blaylock purchased 19,457 shares, increasing his holdings significantly. Pfizer's stock opened at $25.19, with a market cap of $142.88 billion and a P/E ratio of 17.87.

Delta Asset Management LLC TN grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,994 shares of the biopharmaceutical company's stock after purchasing an additional 13,361 shares during the period. Delta Asset Management LLC TN's holdings in Pfizer were worth $2,600,000 as of its most recent SEC filing.

-   Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

A number of other hedge funds have also made changes to their positions in the stock. PSI Advisors LLC lifted its position in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after acquiring an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its holdings in shares of Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton boosted its position in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its stake in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

## Analyst Ratings Changes

Several equities research analysts have recently issued reports on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

-   These Stocks Missed on Earnings, But Will Rebound Next Quarter

**View Our Latest Research Report on PFE**

## Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

## Pfizer Trading Down 1.4 %

-   After a Reset Year, Is Moderna Stock Poised for a Comeback?

Shares of Pfizer stock opened at $25.19 on Thursday. The company has a market cap of $142.88 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company's fifty day simple moving average is $26.12 and its 200-day simple moving average is $26.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the company posted $0.10 earnings per share. The company's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

## About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

## Recommended Stories

-   Five stocks we like better than Pfizer
-   What is the MACD Indicator and How to Use it in Your Trading
-   Energy Transfer: Powering Data With Dividends and Diversification
-   Options Trading - Understanding Strike Price
-   Qualcomm Stock Is Coiling for a Breakout
-   The Top 3 Healthcare Dividend Stocks to Buy and Hold
-   Is Alphabet Too Cheap to Ignore After Its Recent Correction?

**Want to see what other hedge funds are holding PFE?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股盘前热门交易：辉瑞盘前跌 3.56%；Coreweave 盘前涨 3.16% | 辉瑞盘前跌 3.56%；Coreweave 盘前涨 3.16%；Fatpipe 盘前涨 76.63%；Inlif 盘前涨 47.28%；Texxon 盘前涨 34.21%。 | [Link](https://longbridge.com/en/news/274658583.md) |
| 期权热点｜周二 PFE 跌 3%，部分看跌期权飙升 116% | 美东时间 02 月 03 日，辉瑞期权总成交 216437 张，看涨期权占比 59%，看跌期权占比 40%。 | [Link](https://longbridge.com/en/news/274753711.md) |
| 美股盘中速递：脑再生科技跌 12.82%，市场情绪波动显著，资金流向引发关注 | 脑再生科技跌 12.82%；强生跌 1.51%，成交额达到 14.03 亿美元；礼来跌 0.83%，成交额达到 13.12 亿美元；辉瑞跌 1.47%，成交额达到 3.95 亿美元；阿斯利康跌 0.64%，市值达到 3181 亿美元。 | [Link](https://longbridge.com/en/news/276469327.md) |
| 辉瑞在台湾开展新的 Elranatamab 研究，目标是收集现实世界的骨髓瘤数据 | 辉瑞公司（Pfizer Inc.，股票代码：PFE）正在台湾启动一项新的观察性研究，以评估其多发性骨髓瘤药物 elranatamab 在真实世界中的有效性。该研究旨在跟踪患者的治疗结果和治疗模式，尽管尚未开始招募参与者。此举预计将增强辉瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |
| 期权热点｜周三 PFE 涨 3%，部分看涨期权飙升 533% | 美东时间 02 月 04 日，辉瑞期权总成交 245077 张，看涨期权占比 76%，看跌期权占比 23%。 | [Link](https://longbridge.com/en/news/274912810.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
